Your browser is no longer supported. Please, upgrade your browser.
Settings
GNCA Genocea Biosciences, Inc. daily Stock Chart
GNCA [NASD]
Genocea Biosciences, Inc.
Index- P/E- EPS (ttm)-1.90 Insider Own11.14% Shs Outstand31.24M Perf Week-2.17%
Market Cap70.29M Forward P/E- EPS next Y-1.54 Insider Trans- Shs Float29.82M Perf Month-14.77%
Income-29.20M PEG- EPS next Q-0.39 Inst Own48.20% Short Float0.43% Perf Quarter-27.18%
Sales- P/S- EPS this Y83.00% Inst Trans1.58% Short Ratio1.10 Perf Half Y-57.63%
Book/sh1.15 P/B1.96 EPS next Y16.30% ROA-59.40% Target Price18.75 Perf Year-51.51%
Cash/sh1.49 P/C1.51 EPS next 5Y- ROE-145.20% 52W Range1.99 - 11.28 Perf YTD-1.94%
Dividend- P/FCF- EPS past 5Y23.70% ROI- 52W High-80.05% Beta2.38
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low13.07% ATR0.18
Employees61 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)35.46 Volatility12.24% 7.16%
OptionableYes Debt/Eq0.43 EPS Q/Q61.00% Profit Margin- Rel Volume2.05 Prev Close2.24
ShortableYes LT Debt/Eq0.26 EarningsOct 24 BMO Payout- Avg Volume117.61K Price2.25
Recom1.50 SMA20-8.28% SMA50-20.39% SMA200-46.44% Volume241,473 Change0.45%
Nov-15-19Initiated SVB Leerink Outperform $7
Jul-08-19Resumed Stifel Buy $13
Mar-01-19Reiterated Needham Buy
Feb-06-18Upgrade Needham Hold → Buy $3
Sep-27-17Downgrade Needham Buy → Hold
Sep-26-17Downgrade Stifel Buy → Hold $15 → $2.50
Jul-25-17Upgrade Needham Hold → Buy $12
Feb-17-17Downgrade Needham Buy → Hold
Apr-01-16Reiterated Stifel Buy $11 → $13
Dec-17-15Initiated UBS Buy $15
Oct-20-15Reiterated Needham Buy $22 → $15
Oct-19-15Reiterated FBR Capital Outperform $20 → $17
Mar-05-14Initiated Needham Buy $22
Mar-03-14Initiated Stifel Buy $25
Nov-14-19 05:00PM  Genocea to Present at the Stifel 2019 Healthcare Conference GlobeNewswire +9.27%
08:30AM  Genocea Biosciences Enters Oversold Territory Zacks
Nov-09-19 09:00AM  Genocea Preclinical Data at SITC Demonstrate that Inhibitory Neoantigens in an Otherwise Protective Vaccine Reverse Anti-Tumor Responses GlobeNewswire
Nov-05-19 08:05AM  Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC) GlobeNewswire
Oct-29-19 07:22AM  Edited Transcript of GNCA earnings conference call or presentation 24-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Oct-24-19 07:00AM  Genocea Provides Corporate Update and Reports Third Quarter 2019 Financial Results GlobeNewswire -6.49%
Oct-17-19 08:00AM  Genocea to Host Third Quarter 2019 Corporate Update Conference Call & Webcast GlobeNewswire
Sep-30-19 01:13PM  Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More Benzinga -5.84%
Sep-27-19 08:00AM  Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference GlobeNewswire
Sep-18-19 09:31AM  Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Zacks
Aug-30-19 08:00AM  Genocea to Present at September Healthcare Conferences GlobeNewswire
Aug-24-19 01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
Aug-05-19 01:13PM  Edited Transcript of GNCA earnings conference call or presentation 25-Jul-19 12:30pm GMT Thomson Reuters StreetEvents
Jul-25-19 07:00AM  Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results GlobeNewswire -7.24%
Jul-18-19 08:00AM  Genocea to Host Quarterly Corporate Update Conference Call & Webcast on July 25th at 8:30 am ET GlobeNewswire
Jun-25-19 08:37AM  Penny Stocks to Buy Using Technical Analysis for June 2019 Investopedia
Jun-24-19 01:58PM  Need To Know: Genocea Biosciences, Inc. (NASDAQ:GNCA) Insiders Have Been Buying Shares Simply Wall St. +5.19%
Jun-20-19 09:52AM  Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock? Zacks -7.79%
Jun-18-19 04:04PM  Genocea Announces Proposed Public Offering of Common Stock GlobeNewswire
Jun-03-19 12:47PM  Genocea Biosciences Rallies 50% On ASCO Presentation Benzinga +19.61%
10:45AM  Put Buyers Blast Red-Hot Genocea Biosciences Stock Schaeffer's Investment Research
09:17AM  Genocea Biosciences shares rocket 101% after biotech announces positive data from early-stage trial of cancer vaccine MarketWatch
07:00AM  Genoceas GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS-selected Neoantigens in Cancer Patients GlobeNewswire
May-31-19 12:44PM  The Genocea Biosciences (NASDAQ:GNCA) Share Price Is Down 97% So Some Shareholders Are Very Salty Simply Wall St. +24.67%
08:00AM  Genoceas GEN-009 Clinical Results Presentation Selected by ASCOs Journal of Clinical Oncology® as a Top 10 Featured Immuno-oncology Abstract GlobeNewswire
May-23-19 05:34PM  Edited Transcript of GNCA earnings conference call or presentation 30-Apr-19 1:00pm GMT Thomson Reuters StreetEvents
May-16-19 01:00PM  Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products GlobeNewswire
08:00AM  Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial GlobeNewswire
Apr-30-19 08:13AM  Genocea Biosciences: 1Q Earnings Snapshot Associated Press -7.88%
08:00AM  Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results GlobeNewswire
Apr-23-19 08:00AM  Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET GlobeNewswire
Apr-03-19 04:01PM  Genocea to Present at 18th Annual Needham Healthcare Conference GlobeNewswire +9.57%
Apr-02-19 01:00PM  Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors GlobeNewswire
Mar-20-19 10:38AM  Top Ranked Momentum Stocks to Buy for March 20th Zacks
Mar-19-19 11:52AM  Edited Transcript of GNCA earnings conference call or presentation 28-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Mar-13-19 08:23AM  Will Genocea Biosciences Continue to Surge Higher? Zacks
Mar-07-19 08:18AM  Top Ranked Momentum Stocks to Buy for March 7th Zacks
Mar-06-19 08:05AM  Genocea to Present at the Cowen & Company 39th Annual Health Care Conference GlobeNewswire -5.71%
Feb-28-19 08:00AM  Genocea Reports Fourth Quarter 2018 Results and Announces Hiring of New Chief Financial Officer GlobeNewswire -18.89%
Feb-21-19 08:00AM  Genocea to Host Quarterly Corporate Update Conference Call & Webcast on February 28 at 9:00 am ET GlobeNewswire +6.84%
Feb-12-19 08:30AM  Genocea Announces Private Placement Financing of Up to $39 Million GlobeNewswire +8.21%
Jan-30-19 02:21PM  How Does Investing In Genocea Biosciences, Inc. (NASDAQ:GNCA) Impact The Volatility Of Your Portfolio? Simply Wall St. +12.50%
Jan-02-19 11:55AM  These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang ACCESSWIRE +46.44%
08:00AM  Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009 GlobeNewswire
Dec-14-18 12:14PM  Read This Before Selling Genocea Biosciences, Inc. (NASDAQ:GNCA) Shares Simply Wall St.
Dec-10-18 08:00AM  Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer GlobeNewswire
Nov-27-18 08:40AM  Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-15-18 08:00AM  Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies GlobeNewswire
Nov-06-18 07:10PM  Edited Transcript of GNCA earnings conference call or presentation 1-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
08:00AM  Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancers (SITC) 33rd Annual Meeting GlobeNewswire
Nov-01-18 08:35AM  Genocea Biosciences: 3Q Earnings Snapshot Associated Press
08:00AM  Genocea Reports Third Quarter 2018 Financial and Operating Results GlobeNewswire
Oct-25-18 08:05AM  Genocea to Host Third Quarter 2018 Financial Results Conference Call & Webcast on November 1, 2018 at 9:00 a.m. ET GlobeNewswire
Oct-19-18 03:07PM  Do Institutions Own Shares In Genocea Biosciences Inc (NASDAQ:GNCA)? Simply Wall St.
Oct-11-18 08:35AM  Analysis: Positioning to Benefit within Genocea Biosciences, Retail Properties of America, Hawkins, QUANTENNA COMMS, Hillenbrand, and Herman Miller Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Oct-09-18 08:35AM  Genocea Announces Upcoming Presentations at SITC 2018 GlobeNewswire
Oct-01-18 07:30AM  Genocea Strengthens Leadership Team: Thomas Davis, M.D. Appointed Chief Medical Officer; Derek Meisner, J.D. Joins as General Counsel GlobeNewswire
Sep-24-18 08:02AM  Genocea to Present at Two October Investor Conferences GlobeNewswire +10.91%
Aug-29-18 08:05AM  Genocea to Present at Two September Investor Conferences GlobeNewswire
Aug-16-18 05:41AM  Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy? Zacks +5.80%
Aug-07-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Genocea Biosciences, Hawkins, Landstar System, American Assets Trust, TriCo Bancshares, and LogMein Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-02-18 03:18PM  Edited Transcript of GNCA earnings conference call or presentation 2-Aug-18 1:00pm GMT Thomson Reuters StreetEvents +14.53%
09:58AM  Genocea Biosciences: 2Q Earnings Snapshot Associated Press
08:04AM  Genocea Reports Second Quarter 2018 Financial and Operating Results GlobeNewswire
07:00AM  Genocea Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-18 08:05AM  Genocea to Host Second Quarter 2018 Financial Results Conference Call & Webcast on August 2, 2018 at 9:00 a.m. ET GlobeNewswire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-01-18 08:04AM  Genocea to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-10-18 09:02AM  Genocea Biosciences: 1Q Earnings Snapshot Associated Press
07:59AM  Genocea Reports First Quarter 2018 Financial and Operating Results GlobeNewswire
May-04-18 08:04AM  Genocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 a.m. ET GlobeNewswire
May-02-18 07:45AM  Market Trends Toward New Normal in City Office REIT, Malibu Boats, Vical, Renasant, Genocea Biosciences, and Lindsay Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +7.21%
Apr-30-18 08:04AM  Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009 GlobeNewswire
Apr-18-18 09:01AM  Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods GlobeNewswire
Apr-09-18 08:05AM  Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines GlobeNewswire
Mar-27-18 05:23AM  Genocea Biosciences a Good Buy and Hold Stock FX Empire -7.89%
Mar-12-18 05:39PM  Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing GlobeNewswire
Mar-08-18 03:23PM  HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies Benzinga +7.66%
Mar-05-18 08:00AM  Genocea to Present at Two March Investor Conferences GlobeNewswire
Mar-02-18 07:30AM  Research Report Identifies AutoZone, Highwoods Properties, Virtu Financial, Genocea Biosciences, LGI Homes, and Agios Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-23-18 05:13PM  Genocea Biosciences Inc (NASDAQ:GNCA): Does The -14.40% Earnings Decline Make It An Underperformer? Simply Wall St.
Feb-15-18 08:33AM  Genocea Biosciences reports 4Q loss Associated Press
08:00AM  Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
06:50AM  Genocea Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Feb-12-18 04:01PM  NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences Board of Directors GlobeNewswire +7.53%
Feb-08-18 08:00AM  Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET GlobeNewswire
Jan-17-18 08:40AM  Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings GlobeNewswire -25.00%
Jan-16-18 04:01PM  Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants GlobeNewswire
Jan-08-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Kelly Services, Genocea Biosciences, Balchem, Federal Signal, Marriott Vacations Worldwide, and International Bancshares New Research Emphasizes Economic Growth GlobeNewswire -5.36%
Jan-03-18 09:58AM  How Do Analysts See Genocea Biosciences Inc (NASDAQ:GNCA) Performing Over The Couple Of Years? Simply Wall St.
Jan-02-18 02:54PM  Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA) Business Wire +6.03%
Dec-28-17 01:41PM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Genocea Biosciences, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 ACCESSWIRE -5.51%
Dec-27-17 08:35PM  Robbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Filed Class Action Business Wire
04:54PM  GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Genocea Biosciences, Inc. To Contact The Firm Business Wire
02:25PM  Scott+Scott, Attorneys at Law, LLP Reminds Investors that the Lead Plaintiff Deadline in Genocea Biosciences, Inc. (GNCA) Class Action is January 2nd Business Wire
12:15PM  GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018 ACCESSWIRE
10:08AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline - January 2, 2018 ACCESSWIRE
Dec-23-17 08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline GNCA GlobeNewswire
Dec-22-17 03:20PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Genocea Biosciences, Inc. - GNCA PR Newswire
Dec-20-17 10:51AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint on Behalf of Genocea Biosciences, Inc. Shareholders and Lead Plaintiff Deadline Set for January 2, 2018 GNCA ACCESSWIRE
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify neoantigens and antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase 1/2a clinical trial, designed to direct a patient's immune system to attack tumor. The company's products pipeline includes GEN-011, a neoantigen adoptive T cell therapy program and GEN-010, a neoantigen vaccine program. The company has a research collaboration with Iovance Biotherapeutics, Inc. to develop neoantigen-targeted tumor-infiltrating lymphocyte products. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sonsini Peter W.10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:52 PM
MAKOWER JOSHUA10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:51 PM
MOTT DAVID M10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:51 PM
SANDELL SCOTT D10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:52 PM
Chang Carmen10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:50 PM
Florence Anthony A. Jr.10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:50 PM
Makhzoumi Mohamad10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:50 PM
BASKETT FOREST10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:49 PM
Behbahani AliDirectorJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:49 PM
New Enterprise Associates 16, 10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:48 PM
BARRIS PETER J10% OwnerJun 24Buy3.502,857,1429,999,9977,225,676Jun 25 04:48 PM
GLAXOSMITHKLINE PLC10% OwnerJun 24Buy3.501,857,1426,499,9973,365,884Jun 26 10:46 AM
Singh NarinderjeetSENIOR VP, PS&MMay 08Option Exercise0.547,2913,93761,873May 09 12:55 PM
Singh NarinderjeetSENIOR VP, PS&MApr 11Option Exercise0.547,2913,93754,582Apr 12 12:11 PM
Singh NarinderjeetSENIOR VP, PS&MMar 18Option Exercise0.547,2913,93747,291Mar 19 10:07 AM
Clark William DPresident and CEOMar 15Option Exercise0.5415,0008,100119,931Mar 18 01:34 PM
Sonsini Peter W.10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:05 PM
MAKOWER JOSHUA10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:03 PM
MOTT DAVID M10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:04 PM
SANDELL SCOTT D10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:04 PM
Florence Anthony A. Jr.10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:02 PM
Makhzoumi Mohamad10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:03 PM
Behbahani AliDirectorFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:02 PM
Chang Carmen10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:02 PM
BARRIS PETER J10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:00 PM
BASKETT FOREST10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:01 PM
New Enterprise Associates 16, 10% OwnerFeb 14Buy0.479,948,2694,688,61934,948,269Feb 19 05:00 PM